{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:56:18Z","timestamp":1793321778878,"version":"4.5.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2007,6,14]],"date-time":"2007-06-14T00:00:00Z","timestamp":1181779200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2007,9,10]]},"DOI":"10.1007\/s00198-007-0394-0","type":"journal-article","created":{"date-parts":[[2007,6,14]],"date-time":"2007-06-14T02:26:55Z","timestamp":1181788015000},"page":"1319-1328","source":"Crossref","is-referenced-by-count":940,"title":["Glucocorticoid-induced osteoporosis: pathophysiology and therapy"],"prefix":"10.1007","volume":"18","author":[{"given":"E.","family":"Canalis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mazziotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,6,14]]},"reference":[{"key":"394_CR1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tem.2006.03.009","volume":"7","author":"G Mazziotti","year":"2006","unstructured":"Mazziotti G, Angeli A, Bilezikian JP et al (2006) Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 7:144\u2013149","journal-title":"Trends Endocrinol Metab"},{"key":"394_CR2","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1007\/s00198-005-2016-z","volume":"16","author":"AC Feldstein","year":"2005","unstructured":"Feldstein AC, Elmer PJ, Nichols GA et al (2005) Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 16:2168\u20132174","journal-title":"Osteoporos Int"},{"key":"394_CR3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.rhu.0000242778.65766.22","volume":"12","author":"LM Cruse","year":"2006","unstructured":"Cruse LM, Valeriano J, Vasey FB et al (2006) Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J Clin Rheumatol 12:221\u2013225","journal-title":"J Clin Rheumatol"},{"key":"394_CR4","first-page":"1651","volume":"33","author":"KG Saag","year":"2006","unstructured":"Saag KG, Gelbach SH, Curtis JR et al (2006) Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol 33:1651\u20131657","journal-title":"J Rheumatol"},{"key":"394_CR5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11914-005-0017-7","volume":"3","author":"E Canalis","year":"2005","unstructured":"Canalis E (2005) Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep 3:98\u2013102","journal-title":"Curr Osteoporos Rep"},{"key":"394_CR6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/BF02405312","volume":"36","author":"E Canalis","year":"1984","unstructured":"Canalis E (1984) Effect of cortisol on periosteal and nonperiosteal collagen and DNA synthesis in cultured rat calvariae. Calcif Tissue Int 36:158\u2013166","journal-title":"Calcif Tissue Int"},{"key":"394_CR7","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1210\/endo-112-3-931","volume":"112","author":"E Canalis","year":"1983","unstructured":"Canalis E (1983) Effect of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity, and deoxyribonucleic acid content in cultured rat calvariae. Endocrinology 112:931\u2013939","journal-title":"Endocrinology"},{"key":"394_CR8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.mce.2005.11.034","volume":"248","author":"M Eijken","year":"2006","unstructured":"Eijken M, Koedam M, van Driel M et al (2006) The essential role of glucocorticoids for proper human osteoblast differentiation and matrix mineralization. Mol Cell Endocrinol 248:87\u201393","journal-title":"Mol Cell Endocrinol"},{"key":"394_CR9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00223-005-0297-z","volume":"79","author":"LB Sher","year":"2006","unstructured":"Sher LB, Harrison JR, Adams DJ et al (2006) Impaired cortical bone acquisition and osteoblast differentiation in mice with osteoblast-targeted disruption of glucocorticoid signaling. Calcif Tissue Int 79:118\u2013125","journal-title":"Calcif Tissue Int"},{"key":"394_CR10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bone.2006.07.012","volume":"40","author":"S Ito","year":"2007","unstructured":"Ito S, Suzuki N, Kato S et al (2007) Glucocorticoids induce the differentiation of a mesenchymal progenitor cell line, ROB-C26 into adipocytes and osteoblasts, but fail to induce terminal osteoblast differentiation. Bone 40:84\u201392","journal-title":"Bone"},{"key":"394_CR11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S8756-3282(02)00687-7","volume":"30","author":"RC Pereira","year":"2002","unstructured":"Pereira RC, Delany AM, Canalis E (2002) Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 30:685\u2013691","journal-title":"Bone"},{"key":"394_CR12","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1210\/en.2003-0868","volume":"145","author":"RC Pereira","year":"2004","unstructured":"Pereira RC, Delany AM, Canalis E (2004) CCAAT\/enhancer binding protein homologous protein (DDIT3) induces osteoblastic cell differentiation. Endocrinology 145:1952\u20131960","journal-title":"Endocrinology"},{"key":"394_CR13","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1128\/MCB.16.8.4128","volume":"16","author":"Z Wu","year":"1996","unstructured":"Wu Z, Bucher NLR, Farmer SR (1996) Induction of peroxisome proliferator-activated receptor g during the conversion of 3T3 fibroblasts into adipocytes is mediated by C\/EBPh, C\/EBPy, and glucocorticoids. Mol Cell Biol 16:4128\u20134136","journal-title":"Mol Cell Biol"},{"key":"394_CR14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0171-2985(11)80541-3","volume":"193","author":"A Wedel","year":"1995","unstructured":"Wedel A, Ziegler-Heitbrock HW (1995) The C\/EBP family of transcription factors. Immunobiology 193:171\u2013185","journal-title":"Immunobiology"},{"key":"394_CR15","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1210\/jc.2005-2226","volume":"91","author":"AV Schwartz","year":"2006","unstructured":"Schwartz AV, Sellmeyer DE, Vittinghoff E et al (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349\u20133354","journal-title":"J Clin Endocrinol Metab"},{"key":"394_CR16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bbrc.2005.01.117","volume":"329","author":"K Ohnaka","year":"2005","unstructured":"Ohnaka K, Tanabe M, Kawate H et al (2005) Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329:177\u2013181","journal-title":"Biochem Biophys Res Commun"},{"key":"394_CR17","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1074\/jbc.M406294200","volume":"280","author":"E Smith","year":"2005","unstructured":"Smith E, Frenkel B (2005) Glucocorticoids inhibit the transcriptional activity of LEF\/TCF in differentiating osteoblasts in a glycogen synthase kinase-3beta-dependent and -independent manner. J Biol Chem 280:2388\u20132394","journal-title":"J Biol Chem"},{"key":"394_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gene.2004.06.044","volume":"341","author":"JJ Westendorf","year":"2004","unstructured":"Westendorf JJ, Kahler RA, Schroeder TM (2004) Wnt signaling in osteoblasts and bone diseases. Gene 341:19\u201339","journal-title":"Gene"},{"key":"394_CR19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","volume":"8","author":"DA Glass","year":"2005","unstructured":"Glass DA, Bialek P, Ahn JD et al (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751\u2013764","journal-title":"Dev Cell"},{"key":"394_CR20","doi-asserted-by":"crossref","first-page":"21162","DOI":"10.1074\/jbc.M501900200","volume":"280","author":"SL Holmen","year":"2005","unstructured":"Holmen SL, Zylstra CR, Mukherjee A et al (2005) Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 280:21162\u201321168","journal-title":"J Biol Chem"},{"key":"394_CR21","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1242\/jcs.00623","volume":"116","author":"Y Kawano","year":"2003","unstructured":"Kawano Y, Kypta R (2003) Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116:2627\u20132634","journal-title":"J Cell Sci"},{"key":"394_CR22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jcb.240570314","volume":"57","author":"AM Delany","year":"1995","unstructured":"Delany AM, Gabbitas BY, Canalis E (1995) Cortisol down regulates osteoblast 1(I) procollagen mRNA by transcriptional and post-transcriptional mechanisms. J Cell Biochem 57:488\u2013494","journal-title":"J Cell Biochem"},{"key":"394_CR23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1359\/JBMR.0301242","volume":"19","author":"Y Liu","year":"2004","unstructured":"Liu Y, Porta A, Peng X et al (2004) Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k. J Bone Miner Res 19:479\u2013490","journal-title":"J Bone Miner Res"},{"key":"394_CR24","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/en.2003-0990","volume":"145","author":"CA O\u2019Brien","year":"2004","unstructured":"O\u2019Brien CA, Jia D, Plotkin LI et al (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835\u20131841","journal-title":"Endocrinology"},{"key":"394_CR25","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1126\/science.281.5381.1312","volume":"281","author":"NA Thornberry","year":"1998","unstructured":"Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science 281:1312\u20131316","journal-title":"Science"},{"key":"394_CR26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1152\/ajplegacy.1971.221.3.669","volume":"221","author":"DJ Baylink","year":"1971","unstructured":"Baylink DJ, Wergedal JE (1971) Bone formation by osteocytes. Am J Physiol 221:669\u2013678","journal-title":"Am J Physiol"},{"key":"394_CR27","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1359\/JBMR.051103","volume":"21","author":"NE Lane","year":"2006","unstructured":"Lane NE, Yao W, Balooch M et al (2006) Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 21:466\u2013476","journal-title":"J Bone Miner Res"},{"key":"394_CR28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.bone.2003.11.026","volume":"34","author":"E Canalis","year":"2004","unstructured":"Canalis E, Bilezikian JP, Angeli A et al (2004) Perspectives on glucocorticoid-induced osteoporosis. Bone 34:593\u2013598","journal-title":"Bone"},{"key":"394_CR29","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","volume":"289","author":"SL Teitelbaum","year":"2000","unstructured":"Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504\u20138.","journal-title":"Science"},{"key":"394_CR30","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","volume":"140","author":"LC Hofbauer","year":"1999","unstructured":"Hofbauer LC, Gori F, Riggs BL et al (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382\u20134389","journal-title":"Endocrinology"},{"key":"394_CR31","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/endo.139.3.5778","volume":"139","author":"J Rubin","year":"1998","unstructured":"Rubin J, Biskobing DM, Jadhav L et al (1998) Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinology 139:1006\u20131012","journal-title":"Endocrinology"},{"key":"394_CR32","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1530\/eje.1.02147","volume":"154","author":"A Dovio","year":"2006","unstructured":"Dovio A, Perazzolo L, Saba L et al (2006) High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. Eur J Endocrinol 154:745\u2013751","journal-title":"Eur J Endocrinol"},{"key":"394_CR33","doi-asserted-by":"crossref","first-page":"44667","DOI":"10.1074\/jbc.M300213200","volume":"278","author":"A Takuma","year":"2003","unstructured":"Takuma A, Kaneda T, Sato T et al (2003) Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J Biol Chem 278:44667\u201344674","journal-title":"J Biol Chem"},{"key":"394_CR34","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1210\/en.2006-0459","volume":"147","author":"D Jia","year":"2006","unstructured":"Jia D, O\u2019Brien CA, Stewart SA et al (2006) Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147:5592\u20135599","journal-title":"Endocrinology"},{"key":"394_CR35","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI28084","volume":"116","author":"HJ Kim","year":"2006","unstructured":"Kim HJ, Zhao H, Kitaura H et al (2006) Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116:2152\u20132160","journal-title":"J Clin Invest"},{"key":"394_CR36","doi-asserted-by":"crossref","first-page":"17124","DOI":"10.1074\/jbc.271.29.17124","volume":"271","author":"V Knauper","year":"1996","unstructured":"Knauper V, Will H, Lopez-Otin C et al (1996) Cellular mechanisms for human procollagenase-3 (MMP-13) activation. J Biol Chem 271:17124\u201317131","journal-title":"J Biol Chem"},{"key":"394_CR37","doi-asserted-by":"crossref","first-page":"16766","DOI":"10.1016\/S0021-9258(19)89457-7","volume":"269","author":"JMP Freije","year":"1994","unstructured":"Freije JMP, Diez-Itza I, Balbin M et al (1994) Molecular cloning and expression of collagenase 3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 269:16766\u201316773","journal-title":"J Biol Chem"},{"key":"394_CR38","doi-asserted-by":"crossref","first-page":"26607","DOI":"10.1074\/jbc.270.44.26607","volume":"270","author":"AM Delany","year":"1995","unstructured":"Delany AM, Jeffrey JJ, Rydziel S et al (1995) Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanisms. J Biol Chem 270:26607\u201326612","journal-title":"J Biol Chem"},{"key":"394_CR39","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/BF02405069","volume":"35","author":"DW Dempster","year":"1983","unstructured":"Dempster DW, Arlot MA, Meunier PJ (1983) Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 35:410\u2013417","journal-title":"Calcif Tissue Int"},{"key":"394_CR40","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/gut.29.3.378","volume":"29","author":"AJ Stellon","year":"1988","unstructured":"Stellon AJ, Webb A, Compston JE (1988) Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis. Gut 29:378\u2013384","journal-title":"Gut"},{"key":"394_CR41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1172\/JCI113885","volume":"83","author":"E Canalis","year":"1989","unstructured":"Canalis E, Centrella M, Burch J et al (1989) Insulin-like growth factor I mediates selected anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 83:60\u201365","journal-title":"J Clin Invest"},{"key":"394_CR42","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1210\/endo.136.10.7664643","volume":"136","author":"S Rydziel","year":"1995","unstructured":"Rydziel S, Canalis E (1995) Cortisol represses insulin-like growth factor II receptor transcription in skeletal cell cultures. Endocrinology 136:4254\u20134260","journal-title":"Endocrinology"},{"key":"394_CR43","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1210\/endo.134.1.7506203","volume":"134","author":"R Okazaki","year":"1994","unstructured":"Okazaki R, Riggs BL, Conover CA (1994) Glucocorticoid regulation of insulin-like growth factor-binding protein expression in normal human osteoblast-like cells. Endocrinology 134:126\u2013132","journal-title":"Endocrinology"},{"key":"394_CR44","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1074\/jbc.271.15.9033","volume":"271","author":"B Gabbitas","year":"1996","unstructured":"Gabbitas B, Pash JM, Delany AM et al (1996) Cortisol inhibits the synthesis of insulin-like growth factor binding protein-5 in bone cell cultures by transcriptional mechanisms. J Biol Chem 271:9033\u20139038","journal-title":"J Biol Chem"},{"key":"394_CR45","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1210\/en.2002-220129","volume":"143","author":"RD Devlin","year":"2002","unstructured":"Devlin RD, Du Z, Buccilli V et al (2002) Transgenic mice overexpressing insulin-like growth factor binding protein-5 display transiently decreased osteoblastic function and osteopenia. Endocrinology 143:3955\u20133962","journal-title":"Endocrinology"},{"key":"394_CR46","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","volume":"102","author":"NE Lane","year":"1998","unstructured":"Lane NE, Sanchez S, Modin GW et al (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627\u20131633","journal-title":"J Clin Invest"},{"key":"394_CR47","doi-asserted-by":"crossref","unstructured":"Huybers S, Naber TH, Bindels RJ et al (2006) Prednisolone-induced Ca2+malabsorption is caused by diminished expression of the epithelial Ca2+channel TRPV6. Am J Physiol Gastrointest Liver Physiol Aug [Epub ahead of print]","DOI":"10.1152\/ajpgi.00317.2006"},{"key":"394_CR48","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1210\/jc.2002-012101","volume":"87","author":"MR Rubin","year":"2002","unstructured":"Rubin MR, Bilezikian JP (2002) The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 87:4033\u20134041","journal-title":"J Clin Endocrinol Metab"},{"key":"394_CR49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00675619","volume":"52","author":"RF Laan","year":"1993","unstructured":"Laan RF, Buijs WC, van Erning LJ et al (1993) Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content. Calcif Tissue Int 52:5\u20139","journal-title":"Calcif Tissue Int"},{"key":"394_CR50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1530\/eje.1.01841","volume":"152","author":"S Bonadonna","year":"2005","unstructured":"Bonadonna S, Burattin A, Nuzzo M et al (2005) Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol 152:199\u2013205","journal-title":"Eur J Endocrinol"},{"key":"394_CR51","first-page":"399","volume":"76","author":"MH Samuels","year":"1993","unstructured":"Samuels MH, Veldhuis J, Cawley C et al (1993) Pulsatile secretion of parathyroid hormone in normal young subjects: assessment by deconvolution analysis. J Clin Endocrinol Metab 76:399\u2013403","journal-title":"J Clin Endocrinol Metab"},{"key":"394_CR52","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1359\/jbmr.1997.12.4.616","volume":"12","author":"MH Samuels","year":"1993","unstructured":"Samuels MH, Veldhuis JD, Kramer P et al (1993) Episodic secretion of parathyroid hormone in post-menopausal women: assessment by deconvolution analysis and approximate entropy. J Bone Miner Res 12:616\u2013623","journal-title":"J Bone Miner Res"},{"key":"394_CR53","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.metabol.2006.01.009","volume":"55","author":"G Mazziotti","year":"2006","unstructured":"Mazziotti G, Cimino V, De Menis E et al (2006) Active acromegaly enhances spontaneous parathyroid hormone pulsatility. Metabolism 55:736\u2013740","journal-title":"Metabolism"},{"key":"394_CR54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1210\/endo.134.1.8275958","volume":"134","author":"P Urena","year":"1994","unstructured":"Urena P, Iida-Klein A, Kong XF et al (1994) Regulation of parathyroid hormone (PTH)\/PTHrelated peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS 17\/2.8 and OK cells. Endocrinology 134:451\u2013456","journal-title":"Endocrinology"},{"key":"394_CR55","first-page":"717","volume":"19","author":"A Giustina","year":"1998","unstructured":"Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717\u2013797","journal-title":"Endocr Rev"},{"key":"394_CR56","first-page":"1301","volume":"74","author":"A Giustina","year":"1992","unstructured":"Giustina A, Bossoni S, Bodini C et al (1992) Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy. J Clin Endocrinol Metab 74:1301\u20131305","journal-title":"J Clin Endocrinol Metab"},{"key":"394_CR57","first-page":"122","volume":"80","author":"A Giustina","year":"1995","unstructured":"Giustina A, Bussi AR, Jacobello C et al (1995) Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab 80:122\u2013129","journal-title":"J Clin Endocrinol Metab"},{"key":"394_CR58","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000061083","volume":"30","author":"F Manelli","year":"2002","unstructured":"Manelli F, Carpinteri R, Bossoni S et al (2002) Growth hormone in glucocorticoid-induced osteoporosis. Front Horm Res 30:174\u2013183","journal-title":"Front Horm Res"},{"key":"394_CR59","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1378\/chest.127.2.515","volume":"127","author":"M Malerba","year":"2005","unstructured":"Malerba M, Bossoni S, Radaeli A et al (2005) Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment. Chest 127:515\u2013521","journal-title":"Chest"},{"key":"394_CR60","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-006-0019-1","volume":"79","author":"TP Staa van","year":"2006","unstructured":"van Staa TP (2006) The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79:129\u2013137","journal-title":"Calcif Tissue Int"},{"key":"394_CR61","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","volume":"42","author":"S Cohen","year":"1999","unstructured":"Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309\u20132318","journal-title":"Arthritis Rheum"},{"key":"394_CR62","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"S Wallach","year":"2000","unstructured":"Wallach S, Cohen S, Reid DM et al (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277\u2013285","journal-title":"Calcif Tissue Int"},{"key":"394_CR63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bone.2006.02.005","volume":"39","author":"A Angeli","year":"2006","unstructured":"Angeli A, Guglielmi G, Dovio A et al (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39:253\u2013259","journal-title":"Bone"},{"key":"394_CR64","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ecl.2005.01.014","volume":"34","author":"JL Shaker","year":"2005","unstructured":"Shaker JL, Lukert BP (2005) Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin North Am 34:341\u2013356","journal-title":"Endocrinol Metab Clin North Am"},{"key":"394_CR65","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200084","volume":"13","author":"TP Staa van","year":"2002","unstructured":"van Staa TP, Leufkens HGM, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a metaanalysis. Osteoporos Int 13:777\u2013787","journal-title":"Osteoporos Int"},{"key":"394_CR66","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00198-003-1426-z","volume":"14","author":"A Cohen","year":"2003","unstructured":"Cohen A, Shane E (2003) Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 14:617\u2013630","journal-title":"Osteoporos Int"},{"key":"394_CR67","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-003-1548-3","volume":"15","author":"M Steinbuch","year":"2004","unstructured":"Steinbuch M, Youket TE, Cohen S (2004) Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 15:323\u2013328","journal-title":"Osteoporos Int"},{"key":"394_CR68","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1046\/j.1365-2265.2003.01888.x","volume":"59","author":"EF Rossum van","year":"2003","unstructured":"van Rossum EF, Koper JW, van den Beld AW et al (2003) Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrinol 59:585\u2013592","journal-title":"Clin Endocrinol"},{"key":"394_CR69","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1210\/jc.2005-0646","volume":"90","author":"H Russcher","year":"2005","unstructured":"Russcher H, Smit P, van den Akker EL et al (2005) Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. J Clin Endocrinol Metab 90:804\u2013810","journal-title":"J Clin Endocrinol Metab"},{"key":"394_CR70","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1210\/jc.2003-031422","volume":"89","author":"EF Rossum van","year":"2004","unstructured":"van Rossum EF, Voorhoeve PG, te Velde SJ et al (2004) The ER22\/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults. J Clin Endocrinol Metab 89:4004\u20134009","journal-title":"J Clin Endocrinol Metab"},{"key":"394_CR71","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00198-005-0026-5","volume":"17","author":"H Kaji","year":"2006","unstructured":"Kaji H, Tobimatsu T, Naito J et al (2006) Body composition and vertebral fracture risk in female patients treated with glucocorticoid. Osteoporos Int 17:627\u2013633","journal-title":"Osteoporos Int"},{"key":"394_CR72","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1210\/er.2003-0031","volume":"25","author":"JW Tomlinson","year":"2004","unstructured":"Tomlinson JW, Walker EA, Bujalska IJ et al (2004) 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25:31\u201366","journal-title":"Endocr Rev"},{"key":"394_CR73","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1359\/jbmr.2001.16.6.1037","volume":"16","author":"MS Cooper","year":"2001","unstructured":"Cooper MS, Bujalska I, Rabbitt E et al (2001) Modulation of 11\u00e2-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 16:1037\u20131044","journal-title":"J Bone Miner Res"},{"key":"394_CR74","doi-asserted-by":"crossref","first-page":"30232","DOI":"10.1074\/jbc.M001286200","volume":"275","author":"LJ Williams","year":"2000","unstructured":"Williams LJ, Lyons V, MacLeod I et al (2000) C\/EBP regulates hepatic transcription of 11beta-hydroxysteroid dehydrogenase type1. A novel mechanism for cross-talk between the C\/EBP and glucocorticoid signaling pathways. J Biol Chem 275:30232\u201330239","journal-title":"J Biol Chem"},{"key":"394_CR75","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1359\/jbmr.2002.17.6.979","volume":"17","author":"MS Cooper","year":"2002","unstructured":"Cooper MS, Rabbitt EH, Goddard PE et al (2002) Osteoblastic 11\u00e2-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 17:979\u2013986","journal-title":"J Bone Miner Res"},{"key":"394_CR76","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1080\/00365520600664276","volume":"243","author":"RA Hogezand van","year":"2006","unstructured":"van Hogezand RA, Hamdy NA (2006) Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol 243:S59\u2013S64","journal-title":"Scand J Gastroenterol"},{"key":"394_CR77","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.berh.2005.06.008","volume":"19","author":"E Romas","year":"2005","unstructured":"Romas E (2005) Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates. Best Pract Res Clin Rheumatol 19:1065\u20131079","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"394_CR78","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s001980200097","volume":"13","author":"S Lekamwasam","year":"2002","unstructured":"Lekamwasam S, Trivedi DP, Khaw KT (2002) An association between respiratory function and bone mineral density in women from the general community: a cross sectional study. Osteoporos Int 13:710\u2013715","journal-title":"Osteoporos Int"},{"key":"394_CR79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0002-9343(02)01297-4","volume":"114","author":"DD Sin","year":"2003","unstructured":"Sin DD, Man JP, Man SF (2003) The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 114:10\u201314","journal-title":"Am J Med"},{"key":"394_CR80","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jocd.2006.01.001","volume":"9","author":"AA Khan","year":"2006","unstructured":"Khan AA, Hanley DA, Bilezikian JP et al (2006) Standards for performing DXA in individuals with secondary causes of osteoporosis. J Clin Densitom 9:47\u201357","journal-title":"J Clin Densitom"},{"key":"394_CR81","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1359\/JBMR.050603","volume":"20","author":"S Bonadonna","year":"2005","unstructured":"Bonadonna S, Mazziotti G, Nuzzo M et al (2005) Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 20:1837\u20131844","journal-title":"J Bone Miner Res"},{"key":"394_CR82","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1359\/jbmr.060112","volume":"21","author":"G Mazziotti","year":"2006","unstructured":"Mazziotti G, Bianchi A, Bonadonna S et al (2006) Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res 21:520\u2013528","journal-title":"J Bone Miner Res"},{"key":"394_CR83","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","volume":"48","author":"TP Staa Van","year":"2003","unstructured":"Van Staa TP, Laan RF, Barton IP et al (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224\u20133229","journal-title":"Arthritis Rheum"},{"key":"394_CR84","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11926-004-0085-1","volume":"6","author":"J Compston","year":"2004","unstructured":"Compston J (2004) US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences. Curr Rheumatol Rep 6:66\u201369","journal-title":"Curr Rheumatol Rep"},{"key":"394_CR85","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1185\/030079903125003062","volume":"20","author":"CA Cefalu","year":"2004","unstructured":"Cefalu CA (2004) Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin 20:341\u2013349","journal-title":"Curr Med Res Opin"},{"key":"394_CR86","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1359\/jbmr.1997.12.11.1883","volume":"12","author":"M Lunt","year":"1997","unstructured":"Lunt M, Felsenberg D, Reeve J et al (1997) Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study. J Bone Min Res 12:1883\u20131894","journal-title":"J Bone Min Res"},{"key":"394_CR87","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1359\/jbmr.2000.15.7.1368","volume":"15","author":"A Olesik","year":"2000","unstructured":"Olesik A, Ott SM, Vedi S et al (2000) Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Min Res 15:1368\u20131375","journal-title":"J Bone Min Res"},{"key":"394_CR88","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11914-006-0004-7","volume":"4","author":"J Carballido-Gamio","year":"2006","unstructured":"Carballido-Gamio J, Majumdar S (2006) Clinical utility of microarchitecture measurements of trabecular bone. Curr Osteoporos Rep 4:64\u201370","journal-title":"Curr Osteoporos Rep"},{"key":"394_CR89","first-page":"51","volume":"16","author":"H Masaki","year":"2006","unstructured":"Masaki H, Miki T (2006) The biochemical markers of bone in steroid (glucocorticoid)-induced osteoporosis (GIOP). Clin Calcium 16:51\u201360","journal-title":"Clin Calcium"},{"key":"394_CR90","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00198-005-1923-3","volume":"17","author":"K Natsui","year":"2006","unstructured":"Natsui K, Tanaka K, Suda M et al (2006) High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int 17:105\u2013108","journal-title":"Osteoporos Int"},{"key":"394_CR91","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1210\/en.2006-0539","volume":"148","author":"H Gilson","year":"2007","unstructured":"Gilson H, Schakman O, Combaret L et al (2007) Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 148:452\u2013460","journal-title":"Endocrinology"},{"key":"394_CR92","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5","volume":"44","author":"American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis","year":"2001","unstructured":"American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496\u20131503","journal-title":"Arthritis Rheum"},{"key":"394_CR93","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2796.2006.01655.x","volume":"259","author":"S Boonen","year":"2006","unstructured":"Boonen S, Vanderschueren D, Haentjens P et al (2006) Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update. J Intern Med 259:539\u2013552","journal-title":"J Intern Med"},{"key":"394_CR94","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1359\/jbmr.2000.15.4.770","volume":"15","author":"A Shiraishi","year":"2000","unstructured":"Shiraishi A, Takeda S, Masaki T et al (2000) Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 15:770\u2013779","journal-title":"J Bone Miner Res"},{"key":"394_CR95","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00198-004-1614-5","volume":"15","author":"RN Nijs de","year":"2004","unstructured":"de Nijs RN, Jacobs JW, Algra A et al (2004) Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D(3) analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15:589\u2013602","journal-title":"Osteoporos Int"},{"key":"394_CR96","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s002239900705","volume":"65","author":"E Schacht","year":"1999","unstructured":"Schacht E (1999) Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue Int 65:317\u2013327","journal-title":"Calcif Tissue Int"},{"key":"394_CR97","doi-asserted-by":"crossref","first-page":"961","DOI":"10.7326\/0003-4819-125-12-199612150-00004","volume":"125","author":"LM Buckley","year":"1996","unstructured":"Buckley LM, Leib ES, Cartularo KS et al (1996) Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 125:961\u2013968","journal-title":"Ann Intern Med"},{"key":"394_CR98","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2005.06.020","volume":"97","author":"RP Heaney","year":"2005","unstructured":"Heaney RP (2005) The Vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 97:13\u201319","journal-title":"J Steroid Biochem Mol Biol"},{"key":"394_CR99","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1359\/jbmr.2002.17.8.1512","volume":"17","author":"S Amin","year":"2002","unstructured":"Amin S, Lavalley MP, Simms RW et al (2002) The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 17:1512\u20131526","journal-title":"J Bone Miner Res"},{"key":"394_CR100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMoa053569","volume":"355","author":"RN Nijs de","year":"2006","unstructured":"de Nijs RN, Jacobs JW, Lems WF et al (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355:675\u2013684","journal-title":"N Engl J Med"},{"key":"394_CR101","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292\u2013299","journal-title":"N Engl J Med"},{"key":"394_CR102","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","volume":"15","author":"DM Reid","year":"2000","unstructured":"Reid DM, Hughes RA, Laan RF et al (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006\u20131013","journal-title":"J Bone Miner Res"},{"key":"394_CR103","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"JD Adachi","year":"2001","unstructured":"Adachi JD, Saag KG, Delmas PD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202\u2013211","journal-title":"Arthritis Rheum"},{"key":"394_CR104","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","volume":"54","author":"TP Staa van","year":"2006","unstructured":"van Staa TP, Geusens P, Bijlsma JW et al (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104\u20133112","journal-title":"Arthritis Rheum"},{"key":"394_CR105","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S1568-9972(03)00056-9","volume":"4","author":"N Franchimont","year":"2003","unstructured":"Franchimont N, Canalis E (2003) Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease. Autoimmun Rev 4:224\u2013228","journal-title":"Autoimmun Rev"},{"key":"394_CR106","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","volume":"104","author":"RL Jilka","year":"1999","unstructured":"Jilka RL, Weinstein RS, Bellido T et al (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439\u2013446","journal-title":"J Clin Invest"},{"key":"394_CR107","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00774-005-0627-2","volume":"23","author":"MF Iu","year":"2005","unstructured":"Iu MF, Kaji H, Naito J et al (2005) Low-dose parathyroid hormone and estrogen reverse alkaline phosphatase activity suppressed by dexamethasone in mouse osteoblastic cells. J Bone Miner Metab 23:450\u2013455","journal-title":"J Bone Miner Metab"},{"key":"394_CR108","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nature02040","volume":"425","author":"LM Calvi","year":"2003","unstructured":"Calvi LM, Adams GB, Weibrecht KW et al (2003) Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425:841\u2013846","journal-title":"Nature"},{"key":"394_CR109","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","volume":"102","author":"NE Lane","year":"1998","unstructured":"Lane NE, Sanchez S, Modin GW et al (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627\u20131633","journal-title":"J Clin Invest"},{"key":"394_CR110","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s001980070111","volume":"11","author":"NE Lane","year":"2000","unstructured":"Lane NE, Sanchez S, Genant HK et al (2000) Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 11:434\u2013442","journal-title":"Osteoporos Int"},{"key":"394_CR111","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00198-002-1312-0","volume":"14","author":"Q Rehman","year":"2003","unstructured":"Rehman Q, Lang TF, Arnaud CD et al (2003) Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 14:77\u201381","journal-title":"Osteoporos Int"},{"key":"394_CR112","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1210\/jc.2003-032066","volume":"89","author":"EC Buxton","year":"2004","unstructured":"Buxton EC, Yao W, Lane NE (2004) Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1\u201334). J Clin Endocrinol Metab 89:3332\u20133336","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-007-0394-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-007-0394-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-007-0394-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T21:09:52Z","timestamp":1628975392000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-007-0394-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,14]]},"references-count":112,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,9,10]]}},"alternative-id":["394"],"URL":"https:\/\/doi.org\/10.1007\/s00198-007-0394-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,14]]}}}